Deep Brain Stimulation for Treatment Resistant Depression
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00367003|
Recruitment Status : Recruiting
First Posted : August 22, 2006
Last Update Posted : November 6, 2017
|Condition or disease||Intervention/treatment|
|Major Depressive Disorder||Device: Deep Brain Stimulator, implantable|
Major Depression is one of the most common and costly of all psychiatric disorders. While depression can be effectively treated in the majority of patients by either medication or some form of evidence-based psychotherapy, up to 20% of patients fail to respond to standard interventions. For these patients, trial-and-error combinations of multiple medications and electroconvulsive therapy are often required (Kennedy and Lam 2003; UK ECT Review Group 2003). For patients who remain severely depressed despite these aggressive approaches, new strategies are needed.
Specific Aim 1. To asses the safety and tolerability of acute and chronic Cg25-DBS.
Specific Aim 2. To assess the antidepressant efficacy of active Cg25-DBS in treatment-resistant depressed patients.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Deep Brain Stimulation for Treatment Resistant Depression|
|Study Start Date :||September 2006|
|Estimated Primary Completion Date :||September 2018|
|Estimated Study Completion Date :||September 2018|
Experimental: DBS for Treatment Resistant Depression
Deep Brain Stimulation for Treatment Resistant Depression.
Device: Deep Brain Stimulator, implantable
Deep Brain Stimulator
- decrease in Hamilton Depression Rating Scale-24 score of at least 50% at 6 months open treatment [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00367003
|United States, Georgia|
|Emory University School of Medicine||Recruiting|
|Atlanta, Georgia, United States, 30322|
|Principal Investigator: Helen Mayberg, M.D.|
|Sub-Investigator: Roberg Gross, M.D., Ph.D.|
|Sub-Investigator: Patricio Riva Posse, MD|
|Sub-Investigator: Steven Garlow, MD|
|Principal Investigator:||Helen Mayberg, M.D.||Emory University|